A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa — Stella
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
(6 sites) United States
University of Florida Jacksonville Ophthalmology, Jacksonville, Florida Bascom Palmer Eye Institute, Miami, Florida Duke Eye Center, Durham, North Carolina Cincinnati Eye Institute, Cincinnati, Ohio OHSU Casey Eye Institute, Portland, Oregon Retina Foundation of the Southwest, Dallas, Texas
Key details Sponsor
Beacon Therapeutics
Enrollment target
~10 participants
Primary completion
June 2027
Age range
12 Years – 50 Years
Last updated February 2026